Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
89% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 31.75   Max: No Debt
Current: No Debt

Equity to Asset 0.81
ABMD's Equity to Asset is ranked higher than
85% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ABMD: 0.81 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.72   Max: 0.94
Current: 0.81

0.72
0.94
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
77% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 234.31 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 30.93
M-Score: -2.77
WACC vs ROIC
16.98%
11.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.53
ABMD's Operating margin (%) is ranked higher than
75% of the 456 Companies
in the Global Medical Devices industry.

( Industry Median: 5.53 vs. ABMD: 5.53 )
ABMD' s 10-Year Operating margin (%) Range
Min: -111.48   Max: 10.46
Current: 5.53

-111.48
10.46
Net-margin (%) 5.14
ABMD's Net-margin (%) is ranked higher than
77% of the 456 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. ABMD: 5.14 )
ABMD' s 10-Year Net-margin (%) Range
Min: -84.54   Max: 9.5
Current: 5.14

-84.54
9.5
ROE (%) 6.15
ABMD's ROE (%) is ranked higher than
75% of the 440 Companies
in the Global Medical Devices industry.

( Industry Median: 5.22 vs. ABMD: 6.15 )
ABMD' s 10-Year ROE (%) Range
Min: -46.87   Max: 11.4
Current: 6.15

-46.87
11.4
ROA (%) 5.06
ABMD's ROA (%) is ranked higher than
79% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 2.73 vs. ABMD: 5.06 )
ABMD' s 10-Year ROA (%) Range
Min: -42.19   Max: 9.27
Current: 5.06

-42.19
9.27
ROC (Joel Greenblatt) (%) 55.48
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 470 Companies
in the Global Medical Devices industry.

( Industry Median: 9.36 vs. ABMD: 55.48 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.77   Max: 90.23
Current: 55.48

-294.77
90.23
Revenue Growth (3Y)(%) 17.50
ABMD's Revenue Growth (3Y)(%) is ranked higher than
92% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ABMD: 17.50 )
ABMD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.2   Max: 26.3
Current: 17.5

-7.2
26.3
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ABMD Guru Trades in Q4 2013

PRIMECAP Management 5,751,990 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 79,323 sh (-69.55%)
» More
Q1 2014

ABMD Guru Trades in Q1 2014

Paul Tudor Jones 11,200 sh (New)
Steven Cohen 11,972 sh (New)
Joel Greenblatt 25,692 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

ABMD Guru Trades in Q2 2014

Jim Simons 97,223 sh (New)
Chase Coleman 1,690,000 sh (New)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 5,726,490 sh (-0.44%)
» More
Q3 2014

ABMD Guru Trades in Q3 2014

Chase Coleman 1,690,000 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 5,664,990 sh (-1.07%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$20.87 - $26.2 $ 49.94115%0
Joel Greenblatt 2014-03-31 New Buy0.01%$25.6 - $30.03 $ 49.9480%25692
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 205.00
ABMD's P/E(ttm) is ranked higher than
72% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 88.80 vs. ABMD: 205.00 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 205

36.46
946.92
Forward P/E 66.67
ABMD's Forward P/E is ranked higher than
81% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 66.67 )
N/A
PE(NRI) 201.30
ABMD's PE(NRI) is ranked higher than
72% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 84.40 vs. ABMD: 201.30 )
ABMD' s 10-Year PE(NRI) Range
Min: 36.03   Max: 820.67
Current: 201.3

36.03
820.67
P/B 11.70
ABMD's P/B is ranked higher than
56% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 4.18 vs. ABMD: 11.70 )
ABMD' s 10-Year P/B Range
Min: 1.58   Max: 11.7
Current: 11.7

1.58
11.7
P/S 10.60
ABMD's P/S is ranked higher than
59% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ABMD: 10.60 )
ABMD' s 10-Year P/S Range
Min: 2.38   Max: 10.62
Current: 10.6

2.38
10.62
PFCF 83.60
ABMD's PFCF is ranked higher than
82% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 83.60 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 83.6

23.56
2462
POCF 75.10
ABMD's POCF is ranked higher than
74% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 58.93 vs. ABMD: 75.10 )
ABMD' s 10-Year POCF Range
Min: 21.88   Max: 463.25
Current: 75.1

21.88
463.25
EV-to-EBIT 179.83
ABMD's EV-to-EBIT is ranked higher than
71% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 74.50 vs. ABMD: 179.83 )
ABMD' s 10-Year EV-to-EBIT Range
Min: -305.5   Max: 694.7
Current: 179.83

-305.5
694.7
Current Ratio 4.99
ABMD's Current Ratio is ranked higher than
85% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. ABMD: 4.99 )
ABMD' s 10-Year Current Ratio Range
Min: 3.18   Max: 15.95
Current: 4.99

3.18
15.95
Quick Ratio 4.49
ABMD's Quick Ratio is ranked higher than
87% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ABMD: 4.49 )
ABMD' s 10-Year Quick Ratio Range
Min: 2.56   Max: 15.43
Current: 4.49

2.56
15.43
Days Inventory 134.77
ABMD's Days Inventory is ranked higher than
76% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 160.07 vs. ABMD: 134.77 )
ABMD' s 10-Year Days Inventory Range
Min: 128.06   Max: 314.91
Current: 134.77

128.06
314.91
Days Sales Outstanding 42.67
ABMD's Days Sales Outstanding is ranked higher than
92% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. ABMD: 42.67 )
ABMD' s 10-Year Days Sales Outstanding Range
Min: 48.41   Max: 160.07
Current: 42.67

48.41
160.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 36.50
ABMD's Price/Net Cash is ranked higher than
86% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 36.50 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.29   Max: 73.96
Current: 36.5

1.29
73.96
Price/Net Current Asset Value 25.50
ABMD's Price/Net Current Asset Value is ranked higher than
80% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 25.50 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 1.16   Max: 409.4
Current: 25.5

1.16
409.4
Price/Tangible Book 16.70
ABMD's Price/Tangible Book is ranked higher than
61% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 7.44 vs. ABMD: 16.70 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1   Max: 16.93
Current: 16.7

1
16.93
Price/DCF (Projected) 8.80
ABMD's Price/DCF (Projected) is ranked higher than
82% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 8.80 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 4.39   Max: 41.45
Current: 8.8

4.39
41.45
Price/Median PS Value 1.70
ABMD's Price/Median PS Value is ranked higher than
67% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ABMD: 1.70 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.3
Current: 1.7

0.38
4.3
Price/Graham Number 12.20
ABMD's Price/Graham Number is ranked higher than
75% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 12.20 )
ABMD' s 10-Year Price/Graham Number Range
Min: 2.97   Max: 15.85
Current: 12.2

2.97
15.85
Earnings Yield (Greenblatt) 0.60
ABMD's Earnings Yield (Greenblatt) is ranked higher than
69% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ABMD: 0.60 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 0.6

0.1
3.7

Analyst Estimate

Mar15 Mar16 Mar17 Mar18
Revenue(Mil) 212 258 312 374
EPS($) 0.22 0.58 1.51 2.08
EPS without NRI($) 0.22 0.58 1.51 2.08

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany,
Abiomed Inc is a Delaware corporation incorporated on June 4, 1987. The Company is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Companys product portfolio includes; Impella 2.5, Impella CP, Impella RP, AB5000, Symphony, and Impella 5.0 & Impella LD. The Companys Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and to provide the flow and pressure needed to compensate for right heart failure. The Company manufactures & sells the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company faces competition from Getinge (Maquet Cardiovascular), Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, Terumo Heart, Inc. and CardiacAssist Inc. The Companys business is subject to extensive federal, state, local and foreign regulation.
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Impressive Numbers That Matter: Abiomed Inc (ABMD), Freescale Semiconductor Ltd (FSL), Apple Inc (AA Jan 28 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 


More From Other Websites
The BBJ's Five Things; Harvard Bio grows; Drizly soaks it in; Golfer v. SEC; Abiomed surges Jan 29 2015
Abiomed hits all-time high on sales, new device clearance Jan 28 2015
Abiomed hits all-time high on sales, new device clearance Jan 28 2015
Midday movers: Petrobras, Advent Software & more Jan 28 2015
Abiomed Stock Soars After Q3 Earnings Stomp Estimates Jan 28 2015
Abiomed Q3 Earnings Impress; Impella RP Gets FDA Approval - Analyst Blog Jan 28 2015
ABIOMED (ABMD) Stock Soars Today on Third Quarter Earnings Beat Jan 28 2015
Accuray (ARAY) Q2 Loss Wider than Expected, Revenues Lag - Analyst Blog Jan 28 2015
ABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 28 2015
Abiomed upgraded by Northland Capital Jan 28 2015
Updates, advisories and surprises Jan 27 2015
Abiomed shares jump on earnings beat, outlook Jan 27 2015
Abiomed raises revenue outlook, wins US approval for heart pump Jan 27 2015
Abiomed beats Street 3Q forecasts Jan 27 2015
Abiomed beats Street 3Q forecasts Jan 27 2015
Abiomed Receives FDA HDE Approval for the Impella RP Jan 27 2015
4:01 pm Abiomed receives FDA HDE approval for the Impella RP; First FDA Approved percutaneous single... Jan 27 2015
Abiomed Receives FDA HDE Approval for the Impella RP Jan 27 2015
Abiomed Announces Third Quarter Fiscal 2015 Record Revenue of $62.0 Million, up 34% Over the Prior... Jan 27 2015
DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape Jan 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK